Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLQ | O75417 | 7/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545297 | 0.83 | NR1H2 (0.46) | NR1H2GAAGLAPOLBTSHR | |
| SCHEMBL545286 | 0.82 | CACNA1G (0.47) | NR1H2GAAGLAPOLBTSHR | |
| SCHEMBL30401867 | 0.81 | NR1H2 (0.51) | NR1H2GAAGLAPOLBTSHR | |
| SCHEMBL374610 | 0.81 | NR1H2 (0.51) | NR1H2GAAGLAPOLBTSHR | |
| Hydrochloric Acid SCHEMBL16054675 | 0.80 | NR1H2 (0.50) | NR1H2GAAGLAPOLBTSHR | |
| SCHEMBL18186334 | 0.78 | RIPK1 (0.46) | RIPK1ACHE | |
| SCHEMBL19951709 | 0.78 | POLQ (0.57) | GAAPOLQSLC6A2SLC6A4EPHX2 | |
| SCHEMBL20214362 | 0.78 | NR1H2 (0.41) | NR1H2GAAGLAPOLBTSHR | |
| SCHEMBL28546904 | 0.77 | EPHX2 (0.44) | TSHRSLC6A4EPHX2ACHE | |
| SCHEMBL4937359 | 0.77 | NR1H2 (0.48) | NR1H2GAAGLAPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3548476-A1 | IRE1 SMALL MOLECULE INHIBITORS | Quentis Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018102751-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | NR1H2 2335/4885GAA 1747/4885GLA 2957/4885 |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | XBP1, ERN2, ERN1 | NR1H2 2335/4885GAA 1747/4885GLA 2957/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | NR1H2 2726/4885GAA 1352/4885GLA 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.